Investigation of the Compatible Stability of Cefpirome Sulfate with Ornidazole / 中国药房

OBJECTIVE:To investigate the compatible stability of cefpirome sulfate with ornidazole. METHODS:At room temperature [(20±1)℃],the appearances(color,clarity,sedimentation and gas)and pH changes of the mixtures by Cefpirome sulfate for injection with Ornidazole for injection in 0.9% Sodium chloride injection and 5% Glucose injection after 0,1,2,4,6 h were observed. RP-HPLC was adopted to determine its content changes. RESULTS:No significant change was noted for the mix-ture in appearance within 6 h,pH value ranged in 3.359-3.588;compared with the beginning(0 h),the contents of cefpirome sul-fate and ornidazole ranged in 100.2%-100.3%,99.9%-100.4% in 0.9% Sodium chloride injection at each time point,as well as 99.7%-99.9%,99.4%-99.6%in 5%Glucose injection. CONCLUSIONS:At room temperature,cefpirome sulfate mixed with orni-dazole show stable appearance,pH value and content in 0.9%Sodium chloride injection and 5%Glucose injection within 6 h.

Disposition kinetics and urinary excretion of cefpirome after intravenous injection in buffalo calves

We investigated the disposition kinetics and urinary excretion of cefpirome in buffalo calves after a single intravenous administration of 10 mg/kg. Also, an appropriate dosage regimen was calculated. At 1 min after injection, the concentration of cefpirome in the plasma was 57.4 +/- 0.72 microgram/ml, which declined to 0.22 +/- 0.01 microgram/ml at 24 h. The cefpirome was rapidly distributed from the blood to the tissue compartment as shown by the high distribution coefficient values (8.67 +/- 0.46/h), and by the drug's rate of transfer constant from the central to the peripheral compartment, K12 (4.94 +/- 0.31/h). The elimination halflife and the volume of distribution were 2.14 +/- 0.02 h and 0.42 +/- 0.005 l/kg, respectively. Once the distribution equilibrium was reached between the tissues and plasma, the total body clearance (ClB) and the ratio of the drug present in the peripheral to the central compartment (T/P ratio) were 0.14 +/- 0.002 l/kg/h and 1.73 +/- 0.06, respectively. Based on the pharmacokinetic parameters we obtained, an appropriate intravenous cefpirome dosage regimen for treating cefpiromesensitive bacteria in buffalo calves would be 8.0 mg/kg repeated at 12 h intervals for 5 days, or until persistence of the bacterial infection occurred.

The Clinical Effects of Cefpirome for the Treatment of Acute Lower Respiratory Infection / 영남의대학술지

BACKGROUND: In contrast to a healthy person, patients who have acute lower pespiratory tract infection with underlying pulmonary diseases have various pathogens, a rapidly progressie downhill course, and a poor response to prior antimicrobial therapy. Broad spectrum antivacterial therapy is needed for full evaluation. MATERIALS AND METHODS: To evaluate the efficacy and safety of cefpirome, we administered 1gm cefpirome, twice a day to 30 patients who had signs and symptoms of acute lower repiratory infection regardless of their underlying disease, except to those who had an allergic history to antibiotics or severe systemic diseases. RESULTS: The results were as follows : 1) Among 30 cases, 21 cases(70.0%) showed excellent improvement, and 7 cases(23.3%) showed good improvement in their symptoms and signs of acute lower respiratory infection. 2) In 14 cases with isolated pathogens, we observed bacteriologic eradication in 11 cases(78.6%). 3) Significant side effects were not found CONCLUSION: Above results suggest that cefpirome was effective as a monotherapy in patients with acute lower respriatory infection, especially on those with as underlying chronic obstructive pulmonary disease(COPD).

In Vitro Activities of Cefpirome Against the Bacteria Isolated from the Patients in ICU, Oncology and Hematology Units / 감염

BACKGROUND: Infections due to antimicrobial resistant bacteria pose serious problem in the care of the patients in intensive care units, oncology and hematology. It was to determine the prevalent species and cefpirome susceptibilities of the current isolates from these patients. METHODS: Bacteria isolated from patients in the intensive care units, oncology and hematology in a fertiary care university hospital in 1997 were analyzed for the prevalent species. Antimicrobial susceptibility of the strains, most of which were isolated in 1997, was tested by the NCCLS agar dilution method. RESULTS: The proportion of potential pathogens isolated were: Staphylococcus aureus 16.1%, Acinetobacter baumannii 13.6%, Enterobacter-Serratia-Citrobacter group 12.1%, Enterococcus spp. 11.0% and Pseudomonas aeruginosa 10.4%. The lowest resistance rates were : A.baumannii to ampicillin/sulbactam (38%), P. aeruginosa to ceftazidime (37%), Providencia spp. to ceftriaxone (7%), S. marcescens to ceftazidime and cefpirome (10%), and E. coli (3%), K. pneumoniae (10%), E. cloacae (17%) and C. freundii (7%) to cefpirome. All isolates of penicillin-resistant Streptococcus pneumoniae were susceptible to cefpirome. CONCLUSION: The in vitro test suggests that cefpirome should be more useful than the other generations of cephalosporins for the treatment of various nosocomial infections including those due to the 3rd generation cephalosporin-resistant E. cloacae, S. marcescens, C. freundii and penicillin-resistant S. pneumoniae.